Release date: 12 November 2018
Promoter – Financial Intermediary
NEWRON PHARMACEUTICALS SPALocation
Description
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system. The company is operational and already has one drug on the market (Xadago). The investment programme consists of the discovery, pre-clinical and clinical development of a portfolio of assets, addressing different therapeutic areas focusing on underserved neurological conditions. The candidates are at various developmental stages.
Objectives
This project will help provide novel therapies for patients with underserved neurological conditions.
Sector(s)
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 40 million
Total cost (Approximate amount)
EUR 92 million
Environmental aspects
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Status
Signed - 29/10/2018
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).